ABBV vs ABT
AbbVie Inc. vs Abbott Laboratories · Updated Jun 26, 2026
ABBV — 13 winsABT — 10 wins
Price Performance
ABBV +30.17%ABT -30.25%
Performance
| ABBV | ABT | |
|---|---|---|
| 1 Month | +14.36% | +7.70% |
| 3 Months | +18.19% | -11.11% |
| 6 Months | +6.94% | -25.59% |
| YTD | +6.67% | -25.50% |
| 1 Year | +31.36% | -29.95% |
| 3 Year | +76.85% | -12.10% |
| 5 Year | +112.12% | -15.19% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | +6.0% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
| ABT | -24.9% | +10.4% | +3.0% | +0.5% | -21.0% | +29.0% | +25.9% | +25.0% | +23.0% | +46.1% | -10.5% | +0.0% |
Valuation
| ABBV | ABT | |
|---|---|---|
| P/E Ratio | 119.52 | 26.00 |
| Forward P/E | 15.20 | 16.13 |
| PEG Ratio | 7.45 | 2.32 |
| P/S Ratio | 6.47 | 3.39 |
| P/B Ratio | 14.78 | 2.31 |
| EV/EBITDA | 27.77 | 17.19 |
Financials
| ABBV | ABT | |
|---|---|---|
| EPS (TTM) | $2.04 | $3.59 |
| Gross Margin | +83.54% | +56.28% |
| Operating Margin | +31.56% | +16.50% |
| Net Margin | +4.66% | +9.65% |
| ROE | +13.23% | +9.50% |
| ROA | +2.67% | +5.07% |
| Debt/Equity | 2.65 | 0.52 |
Growth
| ABBV | ABT | |
|---|---|---|
| Revenue Growth YoY | +12.43% | +7.78% |
| Revenue Growth QoQ | -9.72% | -2.57% |
| EPS Growth YoY | -45.83% | -18.24% |
| EPS Growth QoQ | -61.76% | -39.22% |
Technical
| ABBV | ABT | |
|---|---|---|
| RSI (14) | 72.66 | 66.33 |
| % From 20-Day SMA | +8.70% | +4.73% |
| % From 50-Day SMA | +13.95% | +4.55% |
| % From 200-Day SMA | +10.27% | -17.33% |
| % From 52-Week High | -0.44% | -32.87% |
| % From 52-Week Low | +34.12% | +13.88% |
Analyst Ratings
ABBV
Buy(19 analysts)
Strong SellHoldStrong Buy
Price Target
$256.92
+18.68% upside
ABT
Buy(29 analysts)
Strong SellHoldStrong Buy
Price Target
$127.46
+44.37% upside
Overview
| ABBV | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| Exchange | NYSE | NYSE |
| Market Cap | $406.47B | $152.89B |
| Shares Outstanding | 1.77B | 1.74B |
| Avg Volume (10D) | 7.01M | 16.19M |
| Dividend Yield | 2.93% | 2.78% |
Frequently Asked Questions
Is ABBV or ABT a better buy right now?
Based on 23 comparable metrics, ABBV leads in 13 categories while ABT leads in 10. ABBV has a consensus analyst rating with 19 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, ABBV or ABT?
Over the past year, ABBV returned +31.36% compared to ABT's -29.95%. In the short term (1 month), ABBV returned +14.36% vs ABT's +7.70%.
Is ABBV or ABT more expensive?
ABBV trades at a P/E of 119.52 compared to ABT's 26.00. On a price-to-sales basis, ABBV trades at 6.47x vs ABT's 3.39x. Forward P/E: ABBV at 15.20 vs ABT at 16.13.
Which stock has higher growth, ABBV or ABT?
ABBV's revenue grew +12.43% year-over-year compared to ABT's +7.78%. EPS growth: ABBV at -45.83% vs ABT at -18.24%.
Do ABBV and ABT pay dividends?
ABBV pays a dividend with a yield of 2.93%. ABT pays a dividend with a yield of 2.78%.
Which stock do analysts prefer, ABBV or ABT?
ABBV has 19 analysts with a target price of $256.92 (+18.68% upside). ABT has 29 analysts with a target of $127.46 (+44.37% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.